Stay updated with breaking news from Lugano Classification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive first data from a cohort of a pivotal Phase 2 trial evaluating...
49% objective response rate (ORR) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR)Even i...
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma